Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Amarin Corporation plc (NASDAQ: AMRN) has reached a settlement agreement with Apotex Inc., resolving patent litigation regarding a generic version of VASCEPA (icosapent ethyl). The agreement prohibits Apotex from selling the generic version in the U.S. until August 9, 2029, unless specific conditions allow for earlier approval. This settlement avoids further litigation costs for Amarin and resolves potential future litigation linked to VASCEPA's cardiovascular risk indication. The deal is subject to federal review and does not involve any financial payment from Amarin.
Amarin Corporation plc (NASDAQ:AMRN) announced plans to enhance promotion and education for VASCEPA® (icosapent ethyl), targeting high-risk cardiovascular patients. Following its FDA approval in December 2019, awareness is crucial as many healthcare providers and patients are unaware of VASCEPA's unique benefits. Amarin intends to restore $80 million in marketing efforts and resume face-to-face interactions with healthcare providers by late June 2020. Prescription growth has slowed due to COVID-19, but patient visits are increasing. The company also anticipates potential impacts from ongoing patent litigation concerning generic versions of VASCEPA.
Amarin Corporation plc (NASDAQ:AMRN) is supporting a clinical trial to examine the effects of icosapent ethyl (IPE) on inflammatory biomarkers in COVID-19 patients. Sponsored by the Canadian Medical and Surgical Knowledge Translation Research Group, the trial is led by Dr. Subodh Verma and Dr. Deepak L. Bhatt. The primary endpoint is the impact of VASCEPA on high-sensitivity C-reactive protein levels after 14 days. Given the potential risks of COVID-19 in cardiovascular patients, VASCEPA may offer beneficial effects. The study aims to assess various outcomes and may lead to larger studies if positive results are observed.
Amarin Corporation (NASDAQ:AMRN) announced new findings from the REDUCE-IT study, revealing a 34% reduction in first coronary revascularizations and a 36% reduction in total revascularizations with VASCEPA (icosapent ethyl) compared to placebo. The study indicated significant decreases in urgent, emergent, and elective procedures. Substantial reductions were also observed in percutaneous coronary intervention (32%) and coronary artery bypass grafting (39%). These results emphasize VASCEPA's potential to positively impact cardiovascular care for patients with elevated triglycerides.
Summary not available.
Summary not available.